Dyne Therapeutics Inc (NAS:DYN)
$ 26 0.05 (0.19%) Market Cap: 2.27 Bil Enterprise Value: 1.85 Bil PE Ratio: 0 PB Ratio: 4.69 GF Score: 37/100

Dyne Therapeutics Inc Advancing FORCE in the Pursuit of Transformative Therapies Transcript

May 03, 2023 / NTS GMT
Release Date Price: $12.07 (+4.41%)
Eric Camino;Ash Dugar
Parent Project for Muscular Dystrophy Research, Inc. - Moderator;Dyne Therapeutics, Inc. -

Hello, everyone. Welcome to today's webinar between PPMD and Dyne Therapeutics. I want to thank you all for joining us this afternoon. We're looking forward to this conversation where we can learn a little bit more about Dyne's FORCE platform in their Phase 1/2 clinical trial with DYNE-251, which is a product for those amenable to exon 51 skipping. Joining me today to walk through the presentation is Ash Dugar the Chief Medical Affairs Officer from Dyne, and we're also joined by Molly White, the VP, Global Head of Patient Advocacy at Dyne.

(Operator Instructions) And of course, we are recording this webinar. So if you have to step away or if you have friends or family members who this might be relevant to please feel free to share it with them. Typically we'll have us up some time likely next week for sharing.

But with that, we can get started for the talk today. So I'm going to hand it over to Ash. He's going to take us through the presentation.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot